- Home
- NUWE vs REVB Comparison
NUWE vs REVB Comparison
Compare NUWE & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- REVB
- Stock Information
- Founded
- NUWE 1999
- REVB 2020
- Country
- NUWE United States
- REVB United States
- Employees
- NUWE N/A
- REVB N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- REVB Health Care
- Exchange
- NUWE Nasdaq
- REVB Nasdaq
- Market Cap
- NUWE 3.9M
- REVB 3.7M
- IPO Year
- NUWE N/A
- REVB N/A
- Fundamental
- Price
- NUWE $0.23
- REVB $0.79
- Analyst Decision
- NUWE Strong Buy
- REVB
- Analyst Count
- NUWE 1
- REVB 0
- Target Price
- NUWE $17.00
- REVB N/A
- AVG Volume (30 Days)
- NUWE 30.9M
- REVB 3.0M
- Earning Date
- NUWE 08-12-2025
- REVB 08-08-2025
- Dividend Yield
- NUWE N/A
- REVB N/A
- EPS Growth
- NUWE N/A
- REVB N/A
- EPS
- NUWE N/A
- REVB N/A
- Revenue
- NUWE $8,787,000.00
- REVB N/A
- Revenue This Year
- NUWE $6.53
- REVB N/A
- Revenue Next Year
- NUWE $51.63
- REVB N/A
- P/E Ratio
- NUWE N/A
- REVB N/A
- Revenue Growth
- NUWE N/A
- REVB N/A
- 52 Week Low
- NUWE $0.21
- REVB $0.74
- 52 Week High
- NUWE $6.61
- REVB $56.00
- Technical
- Relative Strength Index (RSI)
- NUWE 26.12
- REVB 26.64
- Support Level
- NUWE $0.21
- REVB $0.74
- Resistance Level
- NUWE $0.32
- REVB $0.88
- Average True Range (ATR)
- NUWE 0.07
- REVB 0.06
- MACD
- NUWE 0.00
- REVB 0.08
- Stochastic Oscillator
- NUWE 11.43
- REVB 32.49
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).